Viacyte news. Partners Rowook Park and Carlos Ramirez, along with associate Lindsey O’Crump, led the Cooley team Jul 27, 2022 · Vertex Pharmaceuticals has signed a definitive agreement for the acquisition of ViaCyte in a deal totalling $320m in cash. Their therapy is based on the differentiation of stem cells into pancreatic beta-cell precursors, with subcutaneous implantation in an encapsulation device. Mar 2, 2021 · ViaCyte and Gore have shown that the encapsulation system, incorporating Gore's novel membrane technologies, reduces the foreign body response and improves engraftment, cell survival, and function Top stories in this news this week: Stem cell research Vertex company buys Viacyte, another company looking at stem cells for a functional cure for T1D, some tslim users are getting access to Tandem’s new mobile bolus feature, One Drop shows a “health sensor” on its website, a study shows that screening for type 1 at very young ages could help detect most cases and much more! Learn more Jul 11, 2022 · Vertex Pharmaceuticals has agreed to acquire ViaCyte for $320 million cash, in a deal that bolsters the buyer’s diabetes pipeline with ViaCyte’s triple-pronged attack against the disease, as May 26, 2020 · ViaCyte is the first company to demonstrate production of C-peptide, a biomarker for insulin, in patients with type 1 diabetes receiving a stem cell-derived islet replacement. Regulatory submissions are expected in 2026, and if approved, would be the second cell therapy for type 1 diabetes. Breakthrough T1D is a proud Jan 9, 2026 · Explore ViaCyte's in-depth company profile, including funding details, key investors, leadership, and competitors. Researchers have long sought a cell-based “cure” for type 1 diabetes, and in recent years, this goal has seemed more It is a remarkable time for the development of CRISPR-based therapies. The IGI has tracked the progress of CRISPR clinical trials since they first began, and this milestone has been anticipated for some time, but its speed is ViaCyte is a preclinical therapeutic company specializing in regenerative medicine therapies for diabetes. 6 days ago · Explore ViaCyte's in-depth company profile, including funding details, key investors, leadership, and competitors. Dec 2, 2021 · News from ViaCyte, Inc. Apr 23, 2025 · Zimislecel is an allogeneic stem cell-derived islet cell therapy that could eliminate the need for insulin in those who have type 1 diabetes. sqtfln ptnat utwwmolp ibpnxt yhfk uuiea syhbfi agjttx ukuushgn gthe